Response to Comments: MolDX: EndoPredict Breast Cancer Gene Expression Test

This policy (A58696) is a response-to-comments notice concerning the MolDX EndoPredict Breast Cancer Gene Expression Test and does not itself state coverage indications or limits. It notes that the associated LCD L37264 entered notice on 2021-05-20 and becomes effective on 2021-07-04; consult LCD L37264 for the actual coverage criteria and documentation requirements.

"This document contains responses to public comments only and does not define coverage criteria; refer to MolDX LCD L37264 for coverage details. The notice period for LCD L37264 begins 2021-05-20 an..."

Sign up to see full coverage criteria, indications, and limitations.